Adlai Nortye Valuation Multiples

Adlai Nortye Overview

About Adlai Nortye

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Founded

2004

HQ

Employees

123

Website

adlainortye.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $8M

EBITDA: ($43M)

EV

$708M

Valuation Multiples

Multiples.vc

Start free trial

Adlai Nortye Financials

Adlai Nortye reported last 12-month revenue of $8M and negative EBITDA of ($43M).

In the same LTM period, Adlai Nortye generated $8M in gross profit, ($43M) in EBITDA losses, and had net loss of ($29M).

Adlai Nortye P&L

In the most recent fiscal year, Adlai Nortye reported revenue of — and EBITDA of ($48M).

Adlai Nortye expects next 12-month revenue of XXX and NTM EBITDA of XXX

Adlai Nortye Stock Performance

Adlai Nortye has current market cap of $708M, and enterprise value of $708M.

Adlai Nortye's stock price is $12.05.

Adlai Nortye Valuation Multiples

Adlai Nortye trades at 92.5x EV/Revenue multiple, and (16.3x) EV/EBITDA.

Adlai Nortye Financial Valuation Multiples

As of April 11, 2026, Adlai Nortye has market cap of $708M and EV of $708M.

Equity research analysts estimate Adlai Nortye's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Adlai Nortye has a P/E ratio of (24.7x).

Adlai Nortye Margins & Growth Rates

Adlai Nortye's revenue in the last 12 month declined by (36%).

Adlai Nortye's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

Adlai Nortye's rule of 40 is (726%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Adlai Nortye's rule of X is (749%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Adlai Nortye Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Adlai Nortye M&A Activity

Adlai Nortye acquired XXX companies to date.

Last acquisition by Adlai Nortye was on XXXXXXXX, XXXXX. Adlai Nortye acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Adlai Nortye Investment Activity

Adlai Nortye invested in XXX companies to date.

Adlai Nortye made its latest investment on XXXXXXXX, XXXXX. Adlai Nortye invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).